Dark

Check out our Level2View

EQRX
EQRx, Inc. Common Stock
stock NASDAQ

Inactive

Nov 8, 2023

2.34USD-2.092%(-0.05)16,554,640

Pre-market

0.00USD-100.000%(-2.39)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 19, 2022

10:44AM EST EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings Benzinga

Jan 18, 2022

09:42PM EST EQRx Inc. (EQRX), along with its partner CStone Pharmaceuticals, said that sugemalimab plus chemotherapy showed a statistically significant improvement in overall survival or OS compared to placebo plus chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer or NSCLC in the randomized, double-blind Phase 3 GEMSTONE-302 study. RTTNews

07:00PM EST -- Pivotal Phase 3 GEMSTONE-302 trial met key secondary endpoint of prolongation of overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapy -- Overall survival benefit demonstrated regardless of tumor pathologic subtype or PD-L1 expression levels GlobeNewswire Inc

08:22AM EST EQRx Reports 2 Lancet Oncology Publications Post Phase 3 Results Of Sugemalimab In Stage 3, 4 Non-Small Cell Lung Cancer Benzinga

08:00AM EST Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent chemoradiotherapy GlobeNewswire Inc

Jan 10, 2022

11:25AM EST EQRx shares were trading higher after the company announced it entered into a memorandum of understanding with CVS Health. Benzinga

07:41AM EST EQRx Enters Memorandum Of Understanding With CVS Health To Explore Partnership To 'accelerate the commercial availability of lower-cost specialty therapeutics and create cost savings' Through Adoption Of EQRx Medicines Benzinga

07:30AM EST -- The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterprise -- Includes CVS Caremark, the leading pharmacy benefit manager in the U.S., covering 1 in 3 Americans nearly 110 million lives -- Initial focus will be on EQRxs two lead oncology programs with future therapies expected to follow GlobeNewswire Inc

Jan 7, 2022

01:03PM EST EQRx, Geisinger Sign Memorandum Of Understanding To Provide Access To Innovative Cancer Medicines At Lower Costs; Terms Not Disclosed Benzinga

08:00AM EST -- Provides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery network -- Potential to provide access to affordable treatments in areas of high-cost burden for more than 1 million people within Geisinger health systems GlobeNewswire Inc

Jan 3, 2022

08:00AM EST EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that Melanie Nallicheri, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 3:45 p.m. ET. GlobeNewswire Inc

Share